Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview

Abcellera Biologics Inc <ABCL.OQ> expected to post a loss of 14 cents a share - Earnings Preview 
  • Abcellera Biologics Inc ABCL.OQ ABCL.O is expected to show a fall in quarterly revenue when it reports results on August 5 for the period ending June 30 2026

  • The Vancouver British Columbia-based company is expected to report a 54.4% decrease in revenue to $7.784 million from $17.08 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Abcellera Biologics Inc is for a loss of 14 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 2.1% in the last three months. ​

  • Wall Street's median 12-month price target for Abcellera Biologics Inc is $11.00, about 92.6% above its last closing price of $5.71

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2026

-0.20

-0.20

-0.14

Beat

28.5

Dec. 31 2026

-0.18

-0.17

-0.03

Beat

82.8

Sep. 30 2025

-0.16

-0.17

-0.19

Missed

-12.6​

Jun. 30 2025

-0.16

-0.17

-0.12

Beat

27.7

​​Mar. 31 2025

-0.14

-0.14

-0.15

Missed

-5.6

Dec. 31 2024

-0.16

-0.15

-0.11

Beat

28.5​

Sep. 30 2024

-0.15

-0.15

-0.17

Missed

-12.1

Jun. 30 2024

-0.14

-0.14

-0.13

Beat

9.3

This summary was machine generated August 3 at 21:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on AbCellera Biologics

See all news